Jacob Schachter

Research activity per year

If you made any changes in Pure these will be visible here soon.

Filter

2022
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)
Babiker, H., Borazenci, E., Subbiah, V., Agarwala, S., Algazi, A., Schachter, J., Lotem, M., Maurice-Dror, C., Hendler, D., Rahimian, S., Minderman, H., Haymaker, C., Mahadevan, D., Bernatchez, C., Murthy, R., Hultsch, R., Kaplan, N., Woodhead, G., Hennemeyer, C., Chunduru, S., & 3 othersAnderson, P. M., Diab, A. & Puzanov, I., 1 Dec 2022, In: Clinical Cancer Research. 28, 23, p. 5079-5087 9 p.
Research output: Contribution to journal › Editorial
2015

Adoptive transfer of tumor-infiltrating lymphocytes for melanoma: New players, old game
Ben-Ami, E. & Schachter, J., 1 May 2015, In: Immunotherapy. 7, 5, p. 477-479 3 p.
Research output: Contribution to journal › Editorial
1986

Malignant melanoma
Schachter, J., Fenig, E. & Lurie, H., Jul 1986, In: Harefuah. 111, 1-2, p. 48-49 2 p.
Research output: Contribution to journal › Editorial

Research output